Introduction Servier v. Commission (Case T‑691/14) is the second decision of the General Court of the European Union on “pay-for-delay” patent settlements in the pharmaceutical industry,[1] following the 2016 decision of the Court on Lundbeck v. Commission (Case T-472/13).[2] In 2014, the European Commission imposed fines totalling €427.7 million for violations of European competition laws…

Introduction On 27 September 2018, Turkish Competition Authority (“TCA”) published its decision[1] concerning the allegations that Roche Müstahzarları A.Ş.  (“Roche”) had violated articles 4 and 6 of the Law on the Protection of Competition (“Competition Act”). Within this scope, the TCA re-evaluated whether (i) Roche’s agreement with a pharmaceutical wholesaler, Co-Re-Na Ecza Deposu Dış. Tic….

Throughout the last year, the topics of globalization in the markets and digitalization of economy were extensively discussed within the governmental authorities and business community in Russia. One of the major concerns of the authorities and business community was development of competition in “digital era”. The Federal Antimonopoly Service (‘FAS Russia’) has found its pivotal…

Introduction I recommend reading the UK Competition Appeal Tribunal’s (CAT) decision in Flynn/Pfizer vs UK Competition and Markets Authority (CMA) as both lawyers and economists can find a fair number of details to note for later cases related to excessive pricing. In this short article I do not wish to argue whether the CMA’s methodology…

Summary On 7 June 2018, the UK Competition Appeal Tribunal (CAT) held that the UK Competition and Markets Authority (CMA) misapplied the relevant legal test when finding that Pfizer and Flynn Pharma (Flynn) unfairly priced their epilepsy drug. The CAT quashed the record £84.2 million and £5.2 million fines that the CMA imposed on Pfizer…

I. INTRODUCTION In June 2015, Canada’s Competition Bureau released its updated draft of the Intellectual Property Enforcement Guidelines (“Draft IPEGs”) for public review and consultation. The Draft IPEGs are intended to reflect the 2009 amendments to the Competition Act (the “Act”), including the changes to the criminal conspiracy provisions and the introduction of a new…

The U.S. Supreme Court recently issued a decision that provides generic pharmaceutical manufacturers with the ability to challenge the “use codes” listed by brand name manufacturers in filings made with the U.S. Food and Drug Administration (“FDA”). The decision in Caraco v. Novo Nordisk illustrates the impact that these “use codes” can have on the…